Quick Answer
Unicycive Therapeutics, Inc. reported Earnings Per Share Diluted of $1.67 (loss) per share for the year ending 2025.
- Unicycive Therapeutics, Inc. showed an increase of +70.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Unicycive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.13 (loss) per share | Q3 2021: $0.37 (loss) per share | Q1 2022: $0.24 (loss) per share | Q2 2022: $0.24 (loss) per share | Q3 2022: $0.37 (loss) per share | Q1 2023: $0.97 (loss) per share | Q2 2023: $0.29 (loss) per share | Q3 2023: $0.13 (loss) per share | Q1 2024: $0.61 (loss) per share | Q2 2024: $1.50 (loss) per share | Q3 2024: $0.46 (loss) per share | Q1 2025: $0.05 (loss) per share | Q2 2025: $0.52 (loss) per share | Q3 2025: $0.33 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Unicycive Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 94.2%.
- Historical annual values: Fiscal year 2025: $1.67 (loss) per share | Fiscal year 2024: $5.65 (loss) per share | Fiscal year 2023: $1.28 (loss) per share | Fiscal year 2022: $1.20 (loss) per share | Fiscal year 2021: $0.86 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: